Prevalence of incidental and total human immunodeficiency virus, hepatitis B and hepatitis C seropositivity among patients posted for cataract surgery at a tertiary care center in India

Deepak Mishra, Hemendra Singh, Parkshit Gogate, Prashant Bhushan, M K Singh, Tanmay Srivastav, Bageshri Gogate, Smriti Gaur

Purpose: To study the prevalence of human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) viral seropositive among the patients posted for cataract surgery at a tertiary care center in north India. Methods: It was a cross-sectional study done for 30 months duration. All the patients posted for cataract surgery underwent comprehensive ophthalmic evaluation followed by routine hematological workup, including viral markers for HIV, Hepatitis B surface antigen (HBsAg), and anti-HCV. Data were analyzed by the Statistical Package for Social Science (SPSS Version 20). Results: A total of 7,316 individuals underwent cataract surgery from Jan 2016 to August 2018, 4,073/7,316 (55.7%) were males. The prevalence for HIV was 58/7,316 (0.8%), HBsAg was 151/7,316 (2.1%), and HCV was 11/7,316 (0.1%); 28/58 (48.3%) HIV positives were unaware of their seropositivity till testing, as were 37/151 (24.5%) of HBsAg positives, and 4/11 (36.4%) HCV positives. There was a significant relationship between the mean age in the patients with HIV ($P = 0.002$) and anti-HCV ($P = 0.045$). A majority of the seropositive patients were found to be illiterate (45.6%), followed by educated up to high school level (29.1%), and graduate (25.0%). Conclusion: Viral seropositivity was significant among the patients posted for cataract surgery. The eye care providers could refer these patients for counseling and further management for the patient’s and their caretaker’s benefit.

Key words: Cataract, HBsAg, HCV, HIV, viral seropositivity
the patients planned for elective cataract surgery were tested for HBsAg, HCV, and HIV. Congenital and developmental cataracts (involving the pediatric age group) were excluded from the study.

The protocol was approved by the Institutional Ethical Committee and strictly adhered to the Declaration of Helsinki. Preoperatively, all cataract patients underwent comprehensive ocular examination and laboratory investigations. All the patients were requested to sign informed consent for serological evaluation for HBV, HCV, and HIV by rapid diagnostic antibody test kit as recommended by the National AIDS Control Organization (NACO). The patients who were illiterate had the consent readout along with a caregiver and their thumb impressions were obtained. Other laboratory investigations included complete blood count/hemogram and random blood sugar. The HIV was again tested with the Enzyme Linked Immuno-Sorbent Assay (ELISA) test kit. The HIV was considered positive only when both the tests were reported positive in accordance with the NACO guidelines.[14] All blood parameters were investigated in a National Accreditation Board for Hospitals (NABH) certified laboratory. The cost of viral serology testing was Rs. 250 ($3.5) for the hospital for each patient.

Post-test counseling was given to the seropositive cases and they were referred to the antiretroviral therapy (ART) center for registration and baseline investigations. The information recorded was kept confidential. Patients' demographic details like age, gender, education, and occupation were collected. The patients were asked if they had been tested for viral markers earlier, whether they were aware if they had seropositivity. Those who were detected positive were questioned on the previous health care visits, history of blood transfusion, intravenous drug use, and sexual preferences and partners.

The details were recorded on proforma and data were analyzed by using the SPSS (Statistical Package for Social Science) version 25.0. Qualitative data variables were expressed by using frequency and percentage (%). Quantitative data variables were expressed by using mean, SD, etc. The Chi-square test was used to find the association between HBV, HCV, and HIV with age group (years) and gender. The P value <0.05 was considered significant.

Results

A total of 8,067 cataract patients were operated on in the above study period of January 2016 to August 2018. Of these, 7,316/8,067 (90.7%) were adults; 4,073/7,316 (55.7%) were males, while 3,243/7,316 (44.3%) were females. Their ages ranged from 19 to 88 years; 212/7,216 (2.9%) were found to be seropositive for one of the viruses. The average age for seropositive patients was 56.1 years (SD 12.3 years); 128/212 (60.4%) were males, while 84/212 (39.6%) were females. The prevalence for HIV was 58/7,316 (0.8%), HBsAg was 151/7,316 (2.1%), and HCV was 11/7,316 (0.1%). Five were positive for HIV + HBV, two for HIV + HCV, and one for HBV + HCV. The maximum number of individual viral positivity reported was of HBV followed by HIV and HCV. The details of their number and percentages are shown in Fig. 1.

![Flow chart showing number and percentage of incidental and total human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) positivity](image)

Figure 1: Flow chart showing number and percentage of incidental and total human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) positivity
Table 1: Age and gender distribution among the human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) seropositive cases

| Age group | HIV Negative | HIV Positive | Total | P     | Gender | Negative   | Positive | Total | P     |
|-----------|--------------|-------------|-------|-------|--------|------------|----------|-------|-------|
| <40 years | 7 (25%)      | 21 (75%)    | 28    | <0.001| Male   | 86 (67.2%) | 42 (32.8%)| 0     | 0.028|
| 41-60 years | 84 (70.6%) | 35 (29.4%)  | 119   | Chi-square value | Female | 68 (81%) | 16 (19%)  | 0  | Chi-square value |
| >60 years | 63 (96.9%) | 2 (3.1%)    | 65    | 51.51 | Total   | 154       | 58       | 212   | 4.82  |

| HBsAg Age group | Negative | Positive | Total | P     | Gender | Negative | Positive | Total | P     |
|-----------------|----------|----------|-------|-------|--------|----------|----------|-------|-------|
| <40 years       | 20 (71.4%) | 8 (28.6%) | 28   | <0.001| Male   | 38 (29.7%) | 90 (70.3%) | 0 | 0.717 |
| 41-60 years     | 39 932.8% | 80 (67.2%) | 119 | Chi-square value | Female | 23 (27.4%) | 61 (72.6%) | 0 | Chi-square value |
| >60 years       | 2 (3.1%)  | 63 (96.9%) | 65   | 46.72 | Total   | 61        | 151      | 212   | 0.131 |

| HCV Age group | Negative | Positive | Total | P     | Gender | Negative | Positive | Total | P     |
|---------------|----------|----------|-------|-------|--------|----------|----------|-------|-------|
| <40 years     | 28 (100%) | 0        | 28    | 0.175 | Male   | 123 (96.1%) | 5 (3.9%) | 0 | 0.299 |
| 41-60 years   | 110 (92.4%) | 9 (7.6%)  | 119  | Chi-square value | Female | 78 (92.9%) | 6 (7.1%) | 0 | Chi-square value |
| >60 years     | 63 (96.9%) | 2 (2.1%)  | 65   | 3.48  | Total   | 201       | 11       | 212   | 1.08  |

Of the 212, 67 (31.6%) were being detected seropositive for the first time. The patients reported they were unaware of their seropositivity status till then. They were unaware of their viremia so we termed them as incidentally detected seropositive; 28/58 (48.3%) HIV positives were unaware of their status, as were 37/151 (24.5%) of the HBsAg positives and 4/11 (36.4%) HCV positives. Among those who were detected for the first time, one was HIV and HBsAg positive while another one was HBsAg and HCV positive.

The correlation between age group, gender, and seropositive is described in Table 1. There was a significant association with the mean age in the patients with HIV (P < 0.001) and HBsAg seropositive (P < 0.001). There was a significant association between HIV and male gender (P = 0.028). There was no association between gender and HBsAg and HCV positivity.

Among the seropositive patients, a majority of them were found to be illiterate (45.6%) followed by educated up to the high school level (29.1%), and graduate (25.0%). One of the patients who had completed his graduation and was discovered seropositive for HBsAg was a para-medical professional who worked in the intensive care unit.

Discussion

The prevalence of HIV-, HBV-, and HCV-infected patients in India is not insignificant. A recent article in this journal on the preferred practice patterns of the ophthalmologists while operating on the seropositive patients had stated that ophthalmologists considered needle-prick injury an occupational hazard and most took extra precautions while performing cataract surgery on known HIV-positive patients. The United Nations AIDS (UNAIDS) program had a target of 90-90-90: By 2020, 90% of all the people living with HIV will know their HIV status; by 2020, 90% of all the people with diagnosed HIV infection will receive sustained ART, and by 2020, 90% of all the people receiving ART will have viral suppression. Global burden of disease HIV collaborators have stated that the achievement of the new ambitious goals for HIV enshrined in Sustainable Development Goal 3 and the 90-90-90 UNAIDS targets will be challenging. It would need continued efforts from governments, international agencies, and all health care providers in the next 15 years to end AIDS by 2030. In 2017, UNAIDS published a progress report indicating that the global community had reached 70-77-82 of the individuals in each category.

Ophthalmologists can help achieve the 90-90-90 UNAIDS target, which is a WHO goal, by helping in the first 90, and then, help guide them toward achieving the second one. They can help in identifying the seropositive patients, who can then be counseled and referred for further treatment. Their close contacts can be counseled after the patient’s consent and also tested for seropositivity. In Gujarat, of 3,884 married people living with HIV, 1,279 (33%) did not have their partners tested for HIV. Factors including index cases being male, illiterate, aged >25 years, belonging to key populations, substance use, and being in advanced clinical stages were more likely to be associated with partner non-testing. In Gujarat, non-disclosure of HIV status (due to fear of marital discord) and lack of awareness and risk perception were the key barriers to testing.

The process of taking consent for viral seropositivity and the post-test counseling would go a long way to increase the awareness of the diseases, not just among the patients, but even health care providers and caregivers. Nearly half of the HIV of these seropositive cases were unaware of the infection and its source. Through this study, we also tried to highlight the possible source of infection, but our results were based only on the history obtained from the patients. Maddali MV et al. have stated that India can halve the epidemiological burden of HIV over 15 years with the achievement of the UNAIDS 90-90-90 targets. The eye care providers can play a small but not insignificant part in this.
Eye doctors can link patients to HBV and HCV programs. They can help increase awareness, guide patients to appropriate treatment, and help prevent complications. They can help health providers to look for the cause of the infection, and thus, ways to prevent its further spread.\cite{33} HBV vaccination is available. Ophthalmologists and other health care providers should be encouraged to take the HBSAg vaccine. Those who were HIV seropositive can be referred to the local ART centers and counseled about the precautions and care to be taken to prevent further spread of the infection and development of complications. They should be advised about the importance of compliance to ART which is free in India.

In our study, the overall prevalence of HIV was 0.8% and of HBSAg was 2.1% among the patients presenting for cataract surgery. The average estimated prevalence of HBV, HCV, and HIV in the general population in India is 3–4, 0.094–15, and 0.3%, respectively, although regional variations were seen.\cite{35,36}

The prevalence of viral infection was found to be higher in the age group between 50 and 60 years in our study. This may be because people in that decade of life present commonly for cataract surgery. Ahmad et al.\cite{31} and Naeem et al.\cite{30} both from Karachi, Pakistan, reported the highest number of seropositive cases in the age group 50–85 years and 55–64 years, respectively.\cite{34,35}

In our study, the males were more affected than the females for seropositivity, even after accounting for a slight preponderance of males among all hospital-operated cataracts. This could be due to more social mobility in the males, and thus, greater vulnerability to get infected.\cite{32,33,35} Similarly, in a study by Arif et al.\cite{34} done in Aligarh, Uttar Pradesh (the same state as this study), a greater number of male patients were found to be seropositive in comparison to the female patients.

According to Verma et al.,\cite{31} the history of injection from a local practitioner and history of dental extraction were two common risk factors for the HCV infection. Approximately 70% of the health care providers in rural India received no formal training for practicing medicine.\cite{30} A majority of our patients were from rural backgrounds and illiterate, so any of the above reasons may be responsible for their infection.

Since one of our seropositive patients was an intensive care unit worker, he may have been infected by a patient during his career over the past 23 years.

In India, there were numerous cataract surgeries performed in the eye camps in the winter season in this state and there is a mindset that cataract surgery is a one-day admission surgery. Viral seropositivity is not always checked in many situations. Our study strongly recommends viral marker testing in every case of cataract surgery, especially in districts having a high prevalence of HIV.\cite{30}

The cost of cataract surgery in India in high volume settings has been reported to be Rs. 1,000 ($15) to Rs. 4,000 ($42).\cite{34} The additional cost of Rs. 250 ($3.5) for the testing would not greatly add to the cost of surgery, but it would increase the safety for the patient and caregivers. The limitation of our study was that it was a single-center study. It included patients from the local geographical area, therefore, seroprevalence and its pattern may vary in different regions. A large multicenter study would be needed to know the distribution of the types of seropositive cases in different regions. We did not include surgeries other than cataracts, and the pediatric patients were also excluded from our study. We relied on old medical records available and history obtained from the patients. There may be a chance that patients did not disclose their knowledge about viral seropositivity because of social stigma or fear of denial of care. The lack of detailed data on the mode of transmission was another limitation of the study. The false-positive and negatives of the serotesting were also not considered.

**Conclusion**

Since both incidentally detected and total seropositivity were significant in our study, we recommend mandatory screening of viral markers before cataract surgery. This could also help in the early detection and treatment of patients living with viral load. It would help protect them, their contacts, and health care providers. This assumes significance in the Coronavirus disease (COVID-19) pandemic. Viral infections can no longer be neglected in ophthalmic care as the tear film and aqueous have the viral load. The pandemic would make it easier to convince the patients, their caregivers, and the health care providers about the importance of viral seropositivity and the benefits accrued from testing.

**Acknowledgement**

Dr. Manisha Ghate, Deputy Director, National AIDS Research Institute, Pune for her guidance and Dr. Shivani Srivastava Junior resident in RIO, BHU, Varanasi.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. National Program for control of blindness. State wise targets and achievements for various eye diseases during 2015-16.
2. Malik A. Efficacy and performance of various local anesthesia modalities for cataract surgery. J Clin Exp Ophthalmol 2013;51:007.
3. Rewari P, Sharma M, Lohan A, Singh D, Yadav V, Singhal A. Practice pattern of cataract surgeons when operating on seropositive patients. Indian J Ophthalmol 2019;67:335-9.
4. Rishi E, Shantha B, Dhani A, Rishi P, Rajapriya HC. Needle stick injuries in a tertiary eye-care hospital: Incidence, management, outcomes and recommendations. Indian J Ophthalmol 2017;65:995-1003.
5. Ayanniyi AA, Olatunji FO, Majengbasan T, Ayanniyi RO, Danfulani M. Ophthalmic practice health hazards among ophthalmologists in a resource limited setting. Asian Pac J Trop Dis 2011;1:17-20.
6. Belltrami EM, Williams JT, Shapiro CN, Chamberland ME. Risk and management of blood-borne infections in health care workers. Clin Microbiol Rev 2000;13:385-407.
7. Vardell E. Global health observatory data repository. Medical reference services quarterly 2020;39:67-74.
8. World Health Organization. Global hepatitis report 2017. World Health Organization; 2017.
9. Temel A, Seber E, Gunay M. Detection of hepatitis B surface antigen in aqueous humor. Acta Ophthalmol 1990;68:205-8.

10. Atas M, Karatepe Hashas AS, Demircan S, Sanguzel FM, Baskan B, Yuvaç I, et al. The investigation of HCV RNA in tear fluid and aqueous humor in patients with anti-HCV antibody positive who underwent cataract surgery. Ocul Immunol Inflamm 2016;24:297-301.

11. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007;46:160‑70.

12. Rezaee‑Zavareh MS, Hadi R, Karimi‑Sari H, Hossein Khosravi M, Ajudani R, Dolatimehr F, et al. Occult HCV infection. The current state of knowledge. Iran Red Crescent Med J 2015;17:e34181.

13. Sahu GK, McNearney T, Evans A, Turner A, Weaver S, Huang JC, et al. Transient or occult HIV infections may occur more frequently than progressive infections: Changing the paradigm about HIV persistence. Arch Virol Suppl 2005:131‑45.

14. Guidelines for HIV Testing. National AIDS Control Organization; 2008. p. 49‑50.

15. National AIDS Control Organization. Ministry of Health and Family Welfare, Government of India. Available from: nacoline.org. [Last accessed on 2021 Jun 24].

16. Batham A, Narula D, Toteja T, Sreenivas V, Puliyel JM. Systematic review and meta-analysis of prevalence of hepatitis B in India. Indian Paediart 2007;44:663‑74.

17. Overview of hepatitis C Problem in Countries of The South‑East Asia Region. Available from: searo.who.int UNAID 90‑90‑90 resolution. www.unaids.org. [Last accessed on 20 May 01].

18. 90‑90‑90 An ambitious treatment target to help end the AIDS epidemic. Available from: https://www.unaids.org/sites/default/files/media_asset/90‑90‑90_en.pdf [Last accessed 2022-01-24].

19. Global Burden of Disease 2015 HIV Collaborators. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980‑2015: The Global Burden of Disease Study 2015. Lancet HIV 2016;3:e361‑87.

20. UNAIDS. Ending AIDS: Progress toward the 90‑90‑90 Targets. Geneva: UNAIDS; 2017.

21. Selvaraj K, Kumar AMV, Chawla S, Shringarpure KS, Thekkur P, Palanivel C, et al. Are partners of HIV‑infected people being tested for HIV? A mixed-methods research from Gujarat, India. Public Health Action 2017;7:46‑54.

22. Maddali MV, Gupta A, Shah M. Epidemiological impact of achieving UNAIDS 90‑90‑90 targets for HIV care in India: A modeling study. BMJ Open 2016;6:e011914.

23. Recommendations for prevention and control of Hepatitis C virus (HCV) infection and HCV related chronic disease. MMWR Recomm Rep 1998;47:1‑39.

24. Available from: www.who.int/india/publication/technical consultation world hepatitis‑day 2014.pdf.

25. National HIV Counseling and testing Services (HCTS) Guidelines. National AIDS Control Organization. Available from: www.naco.gov.in/sites/default/files. [Last accessed on 2021 Oct 24].

26. Naeem SS, Siddiqui EU, Kazi AN, Khan S, Abdullah FE, Adhi I. Prevalence of Hepatitis B and Hepatitis C among preoperative cataract patients in Karachi. BMC Res Notes 2012;5:492.

27. Ahmad I, Khan SB, Rahman HU, Khan MH, Anwar S. Frequency of Hepatitis B and Hepatitis C among cataract patients. Gomal J Med Sci. 2006;4:61‑4.

28. Khan AJ, Siddiqui TR. Prevalence and importance of Hepatitis B and C screening in cases undergoing elective eye surgery. Pak J Ophthalmol 2007;23:39‑44.

29. Khokar N, Gill ML, Malik GJ. General seroprevalence of Hepatitis C and Hepatitis B virus infection in population. J Col Phys Surg Pak 2004;14:534‑6.

30. Arif SH, Afrose R, Khan AJ, Akram M, Singh SK. Seropositivity rates for Hepatitis B and C viruses in indoor patients of a tertiary care center of Northern India. Int J Curr Microbiol Appl Sci 2015;4:243‑7.

31. Verma R, Behera BK, Jain RB, Arora V, Chayal V, Gill PS. Hepatitis C, a silent threat to the community of Haryana, India: A community‑based study. Australas Med J 2014;7:11‑6.

32. Pulla P. Are India’s quacks the answer to its shortage of doctors? BMJ 2016;352:i291.

33. Joshi RK, Mehendale SM. Determinants of consistently high HIV prevalence in Indian districts: A multi-level analysis. PLoS One 2019;14:e0216321.

34. Jagannath J, Gogate P, Moodley V, Naidoo KS. Comparison of cataract surgery techniques: Safety, efficacy and cost-effectiveness. Eur J Ophthalmol 2014;24:520‑6.